AMMF welcomes NICE’s recommendation that a new life-extending targeted treatment for HER2-positive biliary tract cancers, zanidatamab, should be used by the NHS. Read more at https://ammf.org.uk/2026/04/21/zanidatamab-approved-for-nhs-use-by-nice/

🚨Applications are closing soon for our MB-PhD scheme If you're a University of Manchester, Leeds or St Andrews medical student looking to combine your clinical training with a research PhD, check out our latest opportunities. 📅 Deadline: 9 March 🔗 https://ow.ly/GJQN50XU79k

📢 We’re now accepting poster submissions for our upcoming HPB event! Whether your work focuses on research, translational studies, clinical insights, or patient experience, we want to hear from you. 📧 Send your posters to gmcancer.academy@nhs.net by 12 January 2026 (COP)

Some excellent PhD projects with some amazing research teams!

We have put together a comprehensive catalogue of resources to help you learn more about Cancer of Unknown Primary (CUP). We understand that the unknown is scary. Sometimes knowing information is available can help. Visit www.worldcupalliance.org for free access to resources and research.

We have a position open for a postdoctoral researcher. This is a unique opportunity to develop #liquidbiopsy methods to non-invasively analyse colorectal cancer plasticity and response to treatments. The position is part of the CRC-STARS consortium. @cruknbc.bsky.social cruknbc.org/vacancy-post...

Summer placement opportunity for medical students. Working with @oncocook.bsky.social @aliciamconway.bsky.social and others at the CRUK National Biomarker Centre and The Christie Hospital. Understanding malignancy of unknown origin (MUO). Info below 👇🏻

“Trying to improve CUPiD” AMMF-funded work by Dr Alicia-Marie Conway is adapting the CUPiD platform—originally developed for cancers of unknown primary—to detect confirmed CCA cases. A promising step toward more accurate, non-invasive diagnosis. @cruk-mi.bsky.social #AMMF2025

CUPISCO, highlighted potential of early comprehensive genomic profiling in improving treatment outcomes, suggesting that CGP should be incorporated at initial diagnosis to offer personalized tx options, including immunotherapy for patients with high tumor mutation burden https://buff.ly/4fZbbDy